Literature DB >> 30138121

Prostate cancer multifocality, the index lesion, and the microenvironment.

Rafael R Tourinho-Barbosa1,2, Jean de la Rosette3,4, Rafael Sanchez-Salas1.   

Abstract

PURPOSE OF REVIEW: Most of focal therapies has addressed index lesion as the targeted tumour focus to treat localized prostate cancer (PCa), a multifocal disease. The interaction between tumour foci and host cells creates a tumour microenvironment (TME) which affects tumour growth, cellular proliferation, and PCa progression. This review aims to better understand the biology of cancer foci and their interaction with the prostatic microenvironment after focal therapy. RECENT
FINDINGS: Index lesions are representative of PCa grade in low-risk patients, but the other foci of tumour, the satellite lesions, gain relevance in higher risk patients. Multiparametric MRI, guided biopsies and new biomarkers in combination are important to address PCa multifocality and to adequately select patients to focal therapy. Stromal, immune, and tumoural components are integrated in tumourigenesis and modified after the inflammation induced by focal therapy.
SUMMARY: TME and inflammation play an important role in PCa progression, but further researches are necessary to understand how once protective components of prostate microenvironment become protumour elements and how inflammation induced by focal therapy can affect them. Learning how to modulate TME is an exploratory molecular field that can lead us to better manage PCa in both prevention and treatment scenarios.

Entities:  

Mesh:

Year:  2018        PMID: 30138121     DOI: 10.1097/MOU.0000000000000537

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  12 in total

1.  Imaging and technologies for prostate cancer. Where are we now-where do we go?

Authors:  Jean J M C H de la Rosette; Rafael Sanchez Salas; Art Rastinehad; Thomas J Polascik
Journal:  World J Urol       Date:  2021-03-02       Impact factor: 4.226

Review 2.  Ablative options for prostate cancer management.

Authors:  Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas
Journal:  Turk J Urol       Date:  2020-10-09

3.  Current state of image-guided focal therapy for prostate cancer.

Authors:  Rafael R Tourinho-Barbosa; Bradford J Wood; Andre Luis Abreu; Bruno Nahar; Toshitaka Shin; Selcuk Guven; Thomas J Polascik
Journal:  World J Urol       Date:  2020-05-22       Impact factor: 4.226

4.  Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology.

Authors:  Jeong Hyeon Lee; Seok Ho Kang; Tae Il Noh; Ji Sung Shim; Sung Gu Kang; Jun Cheon; Jeong Gu Lee
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

5.  Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy.

Authors:  Amit Algotar; Chiu-Hsieh Hsu; H H Sherry Chow; Shona Dougherty; Hani M Babiker; David Marrero; Ivo Abraham; Rachit Kumar; Jennifer Ligibel; Kerry S Courneya; Cynthia Thomson
Journal:  JMIR Res Protoc       Date:  2019-02-05

6.  High-grade tumours promote growth of other less-malignant tumours in the same prostate.

Authors:  Sofia Halin Bergström; Stina Rudolfsson; Marie Lundholm; Andreas Josefsson; Pernilla Wikström; Anders Bergh
Journal:  J Pathol       Date:  2021-01-26       Impact factor: 7.996

7.  Combining prostate health index and multiparametric magnetic resonance imaging in estimating the histological diameter of prostate cancer.

Authors:  Po-Fan Hsieh; Tzung-Ruei Li; Wei-Ching Lin; Han Chang; Chi-Ping Huang; Chao-Hsiang Chang; Chi-Rei Yang; Chin-Chung Yeh; Wen-Chin Huang; Hsi-Chin Wu
Journal:  BMC Urol       Date:  2021-11-20       Impact factor: 2.264

8.  Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes.

Authors:  Xi Hong; Liang Mao; Luwei Xu; Qiang Hu; Ruipeng Jia
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

9.  Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy.

Authors:  Mike Wenzel; Felix Preisser; Clarissa Wittler; Benedikt Hoeh; Peter J Wild; Alexandra Tschäbunin; Boris Bodelle; Christoph Würnschimmel; Derya Tilki; Markus Graefen; Andreas Becker; Pierre I Karakiewicz; Felix K H Chun; Luis A Kluth; Jens Köllermann; Philipp Mandel
Journal:  Diagnostics (Basel)       Date:  2021-05-15

10.  Focal therapy for prostate cancer - index lesion treatment vs. hemiablation. A matter of definition.

Authors:  Armando Stabile; Marco Moschini; Francesco Montorsi; Xavier Cathelineau; Rafael Sanchez-Salas
Journal:  Int Braz J Urol       Date:  2019 Sep-Oct       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.